Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells (Q43812139)

27 November 2017

title

Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells (English)

1 reference

27 November 2017

1 reference

6

März W

1 reference

27 November 2017

Scharnagl H

1

1 reference

27 November 2017

Schinker R

2

1 reference

27 November 2017

Gierens H

3

1 reference

27 November 2017

Nauck M

4

1 reference

27 November 2017

Wieland H

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

27 November 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Biochemical Pharmacology

1 reference

27 November 2017

volume

62

1 reference

27 November 2017

issue

11

1 reference

27 November 2017

page(s)

1545-1555

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

A receptor-mediated pathway for cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Defective utilization of cholesterol esters from low-density lipoprotein in a human acute lymphoblastic leukemia T cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

19 Receptor-mediated endocytosis of low-density lipoprotein in cultured cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Human fatty-acid synthase gene. Evidence for the presence of two promoters and their functional interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Discovery, biochemistry and biology of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

In HepG2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. off

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Synthesis and secretion of apolipoprotein B from cultured liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

10.1016/S0006-2952(01)00790-0

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference